2. As of noon trading, Celgene Corporation ( CELG) is down $2.25 (-1.3%) to $169.69 on light volume. Thus far, 763,230 shares of Celgene Corporation exchanged hands as compared to its average daily volume of 2.7 million shares. The stock has ranged in price between $169.30-$171.79 after having opened the day at $171.49 as compared to the previous trading day's close of $171.94.

Celgene Corporation discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. Celgene Corporation has a market cap of $69.6 billion and is part of the health care sector. Shares are up 1.8% year to date as of the close of trading on Thursday. Currently there are 21 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, expanding profit margins, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Celgene Corporation Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

S&P 500 and Dow Score Records With Wall Street Upbeat Ahead of Fed

S&P 500 and Dow on Track for Records With Markets in Good Mood Ahead of Fed

S&P 500 and Dow Aim for New Records With Broad-Based Gains Ahead of Fed

Dow and S&P 500 Reach New Intraday Highs With Markets in Good Mood Ahead of Fed

Teva's New CEO Brings This Secret Weapon